Encelto is the first FDA-approved treatment for macular telangiectasia type 2. The cell therapy slows the loss of macular photoreceptors through continuous delivery of ciliary neurotrophic factor.

Nowadays, congenital gene mutations are the broadly acceptable etiology of vascular malformations ... Some genetic diseases, such as hereditary hemorrhagic telangiectasia or capillary ...

Encelto, the first FDA-approved treatment for MacTel, is implanted intravitreally during a surgery performed by a qualified ophthalmologist. The Food and Drug Administration (FDA) has approved ...

The name comes from a combination from Greek words meaning “water” and “head.” “Congenital” means a person is born with it. The liquid that builds up isn’t water. It’s ...

Congenital adrenal hyperplasia (CAH) is a group of conditions that affect your child’s adrenal glands. Congenital means that your child had this at birth, and hyperplasia means that the glands are ...

The Food and Drug Administration (FDA) has approved Encelto ™ (revakinagene taroretcel-lwey) for the treatment of macular telangiectasia type 2 (MacTel). MacTel is a rare, progressive eye disease that ...

Revakinagene taroretcel-lwey is the first FDA-approved treatment for macular telangiectasia type 2, a progressive neurodegenerative retinal disease. The therapy uses an encapsulated cell-based ...

In some cases, the retinal damage may be irreversible, leading to permanent vision loss even after the medication is discontinued. Macular telangiectasia (MacTel) is an eye disease that affects the ...

The US Food and Drug Administration (FDA) has approved revakinagene taroretcel-lwey (ENCELTO) from Neurotech Pharmaceuticals for the treatment of Macular Telangiectasia type 2 (MacTel). At the date of ...

Livedo reticularis is a mottled discoloration of the skin. The discoloration may appear blotchy with a net-like pattern and range from reddish-blue to purple. 1,2 Although the terms used in the ...

for the treatment of Macular Telangiectasia type 2 (MacTel). MacTel is a neurodegenerative disease of the retina in adults that causes progressive and irreversible vision loss, significantly ...

a private biotech company focused on developing transformative therapies for chronic eye diseases, announced that the U.S. Food and Drug Administration (FDA), has approved ENCELTO™ (revakinagene ...